Resume includes working with Gordon Ramsay

Finally, a Solution to Help Prevent Unnecessary Amputations for Veterans, the Elderly, Diabetics, and Other Wound Victims and Relevant Patient Populations in the US and Internationally

Concept Medical Inc. (CMI) has been granted "Breakthrough Device Designation" from the U.S. Food and Drug Administration (FDA) for MagicTouch PTA (Percutaneous Transluminal Angioplasty), its Sirolimus drug-coated balloon (DCB) catheter, for the treatment of Peripheral Artery Disease (PAD) in Below-the-Knee (BTK). The first 'Breakthrough Device Designation' received by Concept Medical Inc. was on 30th April 2019 for its MagicTouch SCB, for the treatment of Coronary Artery Disease (CAD) in patients with in-stent restenosis.

Dr. Dung Trinh of the Physicians CBD Council to Explore the Latest Data and Research during the Webinar

SpendMend builds momentum as company moves into new stare-of-the-art headquarters and executive team expands

Matching an Individual's Medications Instantly to Drug-to-Drug, Illness, Food, Known Allergies, Lifestyle Choices and Their OWN Unique Genetic (DNA) Profile

Flexible electronics and smart bandages are key to cost savings in the future of advanced wound care

ProSomnus Sleep Technologies is the Leader in Precision Oral Appliance Therapy for OSA

Scottsdale Weight Loss Doctors Expand Nationally Through Video Visits

Law Firm Partners with IT Experts for Comprehensive Solutions

Newest location in New York City set to meet expanding need for the early detection of melanoma and other skin cancers.

North America is the Largest and Asia Pacific the Fastest Growing Regional Market

Dr. Elena Eustache is helping couples become pregnant with Hyperbaric Oxygen Therapy.

Company describes its novel platform model in leading peer-reviewed population health journal

Trial Designed to Test Camsirubicin Against Doxorubicin as First-Line Therapy

United States wearable medical devices market held over 32% revenue share in 2018 and is set to register a significant CAGR up to 2025, owing to increasing incidence of chronic conditions among population.

Patients with terminal, advanced prostate cancer generally have a survival of 2-5 years. The cause of this cancer was unknown and no treatment has been available. Based on 45 years of research, University of Maryland scientists, Dr. Costello and Dr. Franklin, identified the cause of this cancer and a potential treatment. Their treatment terminated this cancer in a patient with expected death in 24 months. This might be the first report of a successful treatment for advanced prostate cancer.

Introducing Jubilant Radiopharma: An Industry-Leading Pharmaceutical Company Specialized in Nuclear Medicine Focused on Developing, Manufacturing, Commercializing and Distributing Diagnostic and Therapeutic Radiopharmaceuticals